NEW YORK, NY--(Marketwire -02\/23\/12)- Biotechnology stocks have performed well of late as companies from across the globe earn more investments. According to a report from Boulder-based data company OnBioVC, biotech companies attracted close to double the amount of investment in the fourth quarter of 2011 than they did in the same period of 2010. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on CEL-SCI Inc. (NASDAQ: CVM - News) & Threshold Pharmaceuticals Inc. (NASDAQ: THLD - News). Access to the full company reports can be found at: <\/p>\n
http:\/\/www.paragonreport.com\/CVM<\/a> <\/p>\n http:\/\/www.paragonreport.com\/THLD<\/a> <\/p>\n According to BIO Industry Analysis survey data, there is renewed optimism surrounding the biotechnology industry among investors amid signs that FDA approvals may be on the rise in 2012. \"The BIO CEO & Investor Conference synthesized the overall mood within the industry of momentum and progress with recent approvals and increased M&A activity, and optimism for the year ahead,\" said Alan Eisenberg, executive vice president of Emerging Companies and Business Development at BIO. <\/p>\n The BIO survey shows that 56 percent of investors think now is a good time to invest -- specifically with early stage companies and those focused on autoimmune disease and oncology. <\/p>\n The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at http:\/\/www.paragonreport.com<\/a> and get exclusive access to our numerous stock reports and industry newsletters. <\/p>\n Biotech stocks have been on an impressive upswing this year, handedly outperforming the broader market. The SPDR S&P Biotech ETF (XBI) -- which holds an equal amount of large companies as well as small companies, translating to increased risks and potentially higher rewards -- is up more than 15 percent year to date. <\/p>\n Earlier this week shares of Threshold Pharmaceuticals skyrocketed more than 40 percent after the company reported that in a mid-stage clinical trial, patients who took its drug candidate TH-302 and an older chemotherapy drug had progression-free survival of 5.6 months, compared to 3.6 months for patients who took only the chemotherapy drug. TH-302 is Threshold's most advanced drug candidate. The company is studying the drug as a treatment for soft tissue sarcoma, solid tumors, leukemia, and several other cancers. <\/p>\n CEL-SCI Corporation researches and develops drugs and vaccines. The company's lead product, Multikine, is under the Phase III clinical trial for the treatment of head and neck cancer. CEL-SCI reported that net loss available to shareholders for the quarter ended December 31, 2011 was ($4,156,833) versus ($6,250,952) during the same quarter ended December 31, 2010. <\/p>\n The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http:\/\/www.paragonreport.com\/disclaimer<\/a>. <\/p>\n<\/p>\n Continued here: NEW YORK, NY--(Marketwire -02\/23\/12)- Biotechnology stocks have performed well of late as companies from across the globe earn more investments. According to a report from Boulder-based data company OnBioVC, biotech companies attracted close to double the amount of investment in the fourth quarter of 2011 than they did in the same period of 2010. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on CEL-SCI Inc Continue reading
\nCEL-SCI and Threshold Pharmaceuticals on the Upswing as FDA Optimism Grows<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"